CCG-203971( CCG-203971 | CCG 203971 )

Catalog No. M18020 CAS No. 1443437-74-8

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

CCG-203971
Note

Research use only, not for human use.
Brief Description

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.
Description

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
In Vitro

——
In Vivo

——
Synonyms

CCG-203971 | CCG 203971
Pathway

Cell Cycle/DNA Damage
Target

DNA/RNA Synthesis
Recptor

others
Research Area

Cancer
Indication

——

CAS Number

1443437-74-8
Formula Weight

408.88
Molecular Formula

C23H21ClN2O3
Purity

>98% (HPLC)
Solubility

DMSO : ≥ 155 mg/mL 379.08 mM; H2O : < 0.1 mg/mL
SMILES

O=C(C1CN(C(C2=CC=CC(C3=CC=CO3)=C2)=O)CCC1)NC4=CC=C(Cl)C=C4
Chemical Name

N-(4-chlorophenyl)-1-[3-(furan-2-yl)benzoyl]piperidine-3-carboxamide